Key Highlights

  • 14.3 is the second quarter 2026 net product revenue, in USD millions, from PEMGARDA reported by Invivyd, Inc. (NASDAQ:IVVD), up 21% from USD 11.8 million a year earlier and USD 28.0 million for the half.
  • 44.4 is the net loss, in USD millions, reported by Invivyd, Inc. (NASDAQ:IVVD) for the quarter ended June 30, 2026, equal to USD 0.14 per share, compared with USD 14.7 million a year earlier.
  • 160.1 is the cash and cash equivalents balance, in USD millions, of Invivyd, Inc. (NASDAQ:IVVD) at June 30, 2026, down from USD 226.7 million at year end, with no Debt shown on the balance sheet.
  • 2,301 is the planned participant count of the DECLARATION Phase 3 trial of VYD2311, the pivotal study at Invivyd, Inc. (NASDAQ:IVVD) whose top-line data were guided for late in the third quarter of 2026.

What Investors Expect From Invivyd, Inc. (NASDAQ:IVVD) on November 16, 2026

Invivyd, Inc. is scheduled to report third quarter 2026 results on November 16, 2026. The comparison base is the second quarter of 2026, when PEMGARDA net product Revenue was USD 14.3 million versus USD 11.8 million, and the net loss was USD 44.4 million, or USD 0.14 per share, versus USD 14.7 million, or USD 0.12 per share. The company did not hold a second quarter Earnings Call and said it plans an investor call after the DECLARATION study is complete.

The Rationale: Last Reported Quarter and Management Outlook for Invivyd, Inc. (NASDAQ:IVVD)

Second quarter Research and Development expense was USD 29.4 million versus USD 9.6 million, and selling, general and administrative expense was USD 29.5 million versus USD 16.6 million, taking total operating expenses to USD 60.1 million and the loss from operations to USD 45.8 million. The company gave no numeric financial guidance. Management said cash is expected to fund operations through the DECLARATION readout and support potential launch readiness for VYD2311. Top-line data from the DECLARATION and LIBERTY Phase 3 studies were guided for late in the third quarter of 2026.

Valuation, Liquidity and Risks for Invivyd, Inc. (NASDAQ:IVVD)

At June 30, 2026, total Assets were USD 218.9 million, total liabilities USD 37.8 million and stockholders' Equity USD 181.1 million, with 294.8 million shares outstanding and an accumulated Deficit of USD 1,040.3 million. Key risks include the termination of the emergency use authorization for PEMGARDA, for which the company received twelve months' advance notice in July 2026 as the underlying declaration is set to end on June 29, 2027, the outcome of the DECLARATION trial, and the need for funding beyond the readout.

Where Things Stand

Invivyd, Inc. (NASDAQ:IVVD) reports third quarter 2026 results on November 16, 2026 with PEMGARDA revenue of USD 14.3 million in the prior quarter and cash of USD 160.1 million at June 30, 2026 set against quarterly operating expenses of USD 60.1 million. The calculated cash burn implied by the first half cash decline of USD 66.6 million shows why the DECLARATION and LIBERTY readouts, guided for late in the third quarter of 2026, matter for funding and for a potential Biologics license application for VYD2311. The release should also clarify the regulatory path for PEMGARDA after the notice of emergency use authorization termination received in July 2026.